O. Plyushch

发表

Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution

F. Ataullakhanov, M. Panteleev, E. Sinauridze, 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Effect of factor VIII on tissue factor-initiated spatial clot growth

F. Ataullakhanov, M. Ovanesov, E. Saenko, 2003, Thrombosis and Haemostasis.

Long‐standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison of age‐matched Danish and Russian patients

S. Lethagen, J. Ingerslev, B. Sørensen, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes.

J. Spira, T. Andreeva, O. Plyushch, 2006, Blood.

Andreev liposomes FS ) reconstituted with pegylated ® recombinant factor VIII ( Kogenate Prolonged bleeding-free period following prophylactic infusion

J. Spira, T. Andreeva, O. Plyushch, 2006 .

Yury Andreev recombinant factor VIII reconstituted with pegylated liposomes Prolonged bleeding-free period following prophylactic infusion of

J. Spira, T. Andreeva, O. Plyushch, 2006 .

Prolonged Bleeding-free Period Following Prophylactic Infusion of Recombinant Factor VIII (Kogenate FS) Reconstituted with Pegylated Liposomes

J. Spira, T. Andreeva, O. Plyushch, 2006 .

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

J. Oldenburg, V. Jiménez‐Yuste, A. Pavlova, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety and efficacy of a long‐acting liposomal formulation of plasma‐derived factor VIII in haemophilia A patients

J. Spira, N. Zozulya, V. Zorenko, 2012, British journal of haematology.

Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII – an open label, exploratory, cross‐over, phase I/II study

J. Spira, N. Zozulya, O. Plyushch, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A

J. Spira, T. Andreeva, O. Plyushch, 2008, Thrombosis and Haemostasis.

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate® in the Observational ObsITI Study,

C. Escuriola-Ettingshausen, V. Vdovin, N. Zozulya, 2011 .

Hemophilia A and B are associated with abnormal spatial dynamics of clot growth.

Mikhail V Ovanesov, F. Ataullakhanov, M. Ovanesov, 2002, Biochimica et biophysica acta.

Effect of factor VIII on tissue factor-initiated spatial clot growth

F. Ataullakhanov, M. Ovanesov, E. Saenko, 2003, Thrombosis and Haemostasis.